Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant paclitaxel and carboplatin for fertility-sparing treatment of FIGO 2018 stage IB2 cervical cancer
2020-000404-11Phase 2Active
- Sponsor
- Princess Margaret Cancer Centre
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Cervical Cancer (CC), sponsored by Princess Margaret Cancer Centre. Primary endpoint: Rate of functional uterus. Started Dec 2020; status: active.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2020-000404-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000404-11.